Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-967-5 | CAS number: 599-61-1
Carcinogenicity
Administrative data
Description of key information
A cohort study on 40.204 Australian Army vetrans assesses long term health effects from exposure to Dapsone during Vietnam service, mortality was assessed for over 30 years since exposure and cancer incidence follow-up was for 19 years. There was no statistically significant difference in non-cancer mortality between those who consumed Dapsone and those who did not. There was a modest but statistically significant lower than expected overall cancer incidence, and for some specific cancers, a lower than expected mortality for the Dapsone exposed group.
This study concludes that those who took the anti-malarial Dapsone/Paludrine prophylaxis have not experienced adverse health, as measured by mortality and cancer incidence, compared to those veterans who took anti-malarial treatment without Dapsone.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- other: retrospective cohort study on Australian Army veterans
Justification for classification or non-classification
A cohort study on 40.204 Australian Army vetrans concludes that those who took the anti-malarial Dapsone/Paludrine prophylaxis have not experienced adverse health, as measured by mortality and cancer incidence, compared to those veterans who took anti-malarial treatment without Dapsone.
Also regarding IARC evaluation, there is no reason to classify Dapsone (4,4'-DDS) as a potential Human carcinogen.
Additional information
Also, according to IARC, Dapsone is not classifiable as carcinogen.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
